Characterization of < em > Acinetobacter baumannii-calcoaceticus < /em > complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK)

This report describes the characterization of the baseline ABC isolates from patients enrolled in ATTACK, including an analysis of the correlation of microbiological outcomes with SUL-DUR MIC values and the molecular drivers of SUL-DUR resistance.PMID:38567976 | DOI:10.1128/aac.01698-23
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Source Type: research